The purpose of this study was to evaluate our initial experience on the use of IMRT in children with tumors in eloquent or critical locations. Twenty-two children with a median age of 12 years (range 1-17) were treated using IMRT for tumors which were within 2 cm of a critical structure. The treatment locations were spine [2], head and neck [5], abdominopelvic [8], and intracranial [7]. Eighty-two percent (82%) of patients were treated with curative intent despite most patients having advanced or metastatic disease and two patients having previously received standard external beam radiation. IMRT was delivered with a 6MV linear accelerator using dynamic multileaf collimators with a median of six fields. The median follow-up was five months . The median administered dose was 45 Gy. The median planning treatment volume (PTV) was 105.4 cc. For the intracranial lesions, the mean doses to the pituitary, brainstem, cochlea, optic nerve, and lens were 31%, 42%, 17%, 27%, and 6% of the total dose, respectively. For the head and neck tumors, the mean doses to the spinal cord and parotid glands were 47% and 49%, respectively. For the pelvic tumors, the mean dose to the bladder, rectum, and small bowel were 51%, 63%, and 22%, respectively.
Introduction
Radiation therapy is an integral component in the management of most pediatric cancers despite concerns about late effects and secondary malignancies (1-6). Over the past twenty years, there has been a trend in the management of pediatric tumors to decrease the administered radiation dose, especially for those childhood tumors where chemotherapy has been effective in increasing response and cure rates (7-9). Additionally, there have been recent technological advancements in radiation therapy, including 3-D conformal therapy and intensity modulated radiation therapy (IMRT), that allow increased localization of the dose to the tumor or region of interest while sparing surrounding critical structures (10). These new technologies have been rapidly incorporated into the management of some adult malignancies, especially cancers of the upper respiratory tract, prostate, and pelvis, resulting in reduced morbidity while delivering an increased tumorcidal dose (11-13).
Currently, limited data exist for the use of IMRT in the treatment of pediatric tumors (14-18). There is concern that IMRT could lead to an increased incidence of secondary malignancies due to the increased total integral dose delivered compared to using conventional or 3-D conformal techniques. Therefore, compared to its use in adults, IMRT has not been incorporated to the same extent in the management of pediatric tumors. However, this technology could be particularly useful for pediatric patients with tumors in critical locations or recurrent tumors with a prior history of radiation. We hypothesized that IMRT could result in substanial sparing of normal structures in the treatment of pediatric tumors in critical locations.
Methods
This retrospective study was approved by the Institutional Review Board (IRB 0411162). From January 2002 thru October 2004, at the University of Pittsburgh Cancer Institute, 22 children with a median age of 12 years (range 1-17) were treated using IMRT (Table I ). All tumors were located within 2 cm of a critical structure. Fourteen children were male and eight were female. (Table I, #7 ) with recurrent medulloblastoma in the posterior fossa after definitive treatment including surgery, chemotherapy, and radiation therapy with repeat surgery and Gamma Knife radiosurgery for recurrence. The second patient, a 13-year-old girl, (Table  I, #22) with Wilm's tumor presented with a recurrence in the lumbar spine after having been treated with two courses of external beam radiation to the same site.
IMRT was delivered with a Varian 6MV linear accelerator using dynamic multi-leaf collimators. Using the Varian Eclipse planning system, the pediatric radiation oncologist contoured the region of interest, the gross tumor volume (GTV), and then subsequently included a 7-10 mm margin to create the planning treatment volume (PTV). The surrounding normal critical structures were contoured and used as dose constraints. For patients with intracranial tumors, the surrounding normal brain tissue, optic chiasm, pituitary, cochlea, and lens were the primary dose volume constraint structures. The priority, or ranking, of these structures depended on the location of the tumor. The higher the ranking of the structure-dose constraint indicates the higher importance of the IMRT plan to attain this goal. For example, the cochlea was the highest priority for patients with posterior fossa tumors whereas the optic chiasm was the highest priority for the patients with hypothalamic tumors. Inverse treatment planning was performed using the Eclipse planning system. Once completed, the IMRT plan was reviewed by the radiation oncologist for approval to initiate treatment. Once radiation treatment began, all patients were evaluated during treatment on a weekly basis for any acute toxicity. Following completion of IMRT, patients were seen in follow-up to assess tumor response and late effects. The median follow-up was five months .
Results
The median dose was 45 Gy (range 21.6-59.4 Gy). The median PTV was 105.4 cc (range 15.5-546.59 cc). The minimum isodose line prescription was 95% (range 95-100%) with a coefficient of variation of 2.6% for all patients. For the intracranial lesions, the mean doses to the pituitary, brainstem, cochlea, optic nerve, and lens were 31%, 42%, 17%, 27%, and 6% of the total dose, respectively. Figure 1 displays the IMRT plan for a 14-year-old girl with medulloblastoma, stage M-0, (Table I , case #8), who had completed cranio-spinal irradiation to a dose of 23.4 Gy using conventional techniques along with cisplatinum based chemotherapy. This IMRT plan shows the posterior fossa delivering a dose of 32 Gy while sparing the cochlea. The patient experienced no Grade 3 or 4 toxicity from this treatment and completed the treatment without any treatment breaks.
For the nasopharynx cancers, the mean dose to the spinal cord and parotid gland were 47% and 49%, respectively. These patients did experience Grade 3 acute mucositis, which was resolved by end of treatment and did not result in any significant treatment interruption. For the pelvic tumors, the mean dose to the bladder, rectum, and small bowel were 51%, 63%, and 22%, respectively. No patients experienced severe acute toxicities. Figure 2 shows the treatment plan for a sixteen-year-old boy ( Table I, #13 ) with metastatic osteosarcoma involving the sixth thoracic vertebrae. IMRT was delivered in order to decrease the dose to the spinal cord while providing sufficient dose to treat his disease. The Planning Treatment Volume (PTV) received 48 Gy while the spinal cord received 16 Gy. He tolerated the IMRT with no significant acute side effects and had effective palliation of his back pain with no neurological sequellae.
One patient did have progression of tumor within the irradiated volume ( 
Discussion
There are other recent reports which support the use of IMRT in children. Penagaricano et al. reported on the feasibility of IMRT in five pediatric patients with different malignancies and showed homogenous dose distributions within the tar-get and a rapid dose gradient outside the target allowing for normal tissue sparing (16). In the study by Huang et al. pediatric patients with medulloblastoma who received cisplatinum based chemotherapy along with irradiation using either 3-D conformal or IMRT were retrospectively compared and patients who received IMRT received a substantially lower dose to the hearing apparatus that resulted in less hearing loss (14) . Our study also supports the use of IMRT for other pediatric malignancies especially where the target volume is close to a sensitive critical structure or in sites previously irradiated. Clearly, a comparison of IMRT with 3-D conformal radiation technique will be particularly valuable for this patient population, which is the topic of our subsequent manuscript in pediatric IMRT.
Even though IMRT appeared beneficial for these particular cases, the use of IMRT still should be used with caution in children as compared to its use in the adult population. IMRT commonly involves using an increased number of fields; thereby, irradiating a large volume to a low dose, which could potentially lead to an increased risk of secondary malignancies (19). Thus, more follow-up is needed to make final conclusions on the use of IMRT for the pediatric population.
